Home » Stocks » TRPXY

Therapix Biosciences Ltd. (TRPXY)

Stock Price: $4.10 USD 0.60 (17.14%)
Updated Jan 22, 2021 9:30 AM EST - Market closed
Market Cap 16.50M
Revenue (ttm) n/a
Net Income (ttm) -4.58M
Shares Out 204.24M
EPS (ttm) 0.64
PE Ratio 6.41
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $4.10
Previous Close $3.50
Change ($) 0.60
Change (%) 17.14%
Day's Open 4.10
Day's Range 4.10 - 4.10
Day's Volume 100
52-Week Range 0.072 - 7.4

News

Hide News
  • All
  • Videos
  • Press Releases
Schaeffers Research - 2 weeks ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks over the past week, and look ahead to how the cannabis ...

Other stocks mentioned: APHA, GNLN, HEXO, IIPR, OGI, SNDL, TRPX
Schaeffers Research - 2 months ago

Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks last week and look ahead at the pot stocks to watch in ...

Other stocks mentioned: ACB, APHA, ARNA, GNLN, GWPH, IIPR, NBEV, OGI, TRPX
PRNewsWire - 6 months ago

TEL AVIV, Israel, July 1, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company" or "Therapix"), a specialty, clinical-stage pharmaceutical company focusing on the develo...

PRNewsWire - 6 months ago

TEL-AVIV, Israel, June 29, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. ("Therapix" or the "Company") (Nasdaq: TRPX), a specialty, clinical-stage pharmaceutical company focusing on the devel...

Investopedia - 11 months ago

The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges.

Other stocks mentioned: ARNA, CARA, CRBP, CRON, GNLN, GWPH, MBII, NBEV, NTEC, OGI, PMD, SNDL, TLRY, TRPX, VFF, ZYNE
Market Watch - 1 year ago

Shares of Therapix Biosciences fell 5% in morning trading after the Israeli drugmaker said it would continue to test its experimental cannabinoid-based therapy as an autism treatment.

Benzinga - 1 year ago

Cannabis-focused investment company SOL Global Investments Corp. (CSE: SOL) said Tuesday that its portfolio company, Heavenly Rx, Ltd., has entered into a memorandum of understanding with Ther...

Forbes - 1 year ago

There is a lot of hype regarding CBD and a lack of regulatory clarity. I discuss the big issues and identify some of the better players in the space among public-traded companies.

Other stocks mentioned: ACB, APHA, CGC, CRON, GWPH, TLRY, TRPX, ZYNE

About TRPXY

Therapix Biosciences, a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Therapix Biosciences Ltd. has a collaboration with The University of Calgary to evaluat... [Read more...]

Industry
Biotechnology
IPO Date
Mar 22, 2017
Stock Exchange
OTCMKTS
Ticker Symbol
TRPXY
Full Company Profile

Financial Performance

Financial Statements